DrugPatentWatch Database Preview
UPTRAVI Drug Profile
When do Uptravi patents expire, and when can generic versions of Uptravi launch?
Uptravi is a drug marketed by Actelion Pharms Ltd and is included in one NDA. There are four patents protecting this drug.
This drug has eighty-three patent family members in twenty-eight countries.
The generic ingredient in UPTRAVI is selexipag. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the selexipag profile page.
Summary for UPTRAVI
| International Patents: | 83 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 41 |
| Clinical Trials: | 2 |
| Patent Applications: | 27 |
| Drug Prices: | Drug price information for UPTRAVI |
| DailyMed Link: | UPTRAVI at DailyMed |
Generic Entry Opportunity Date for UPTRAVI
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for UPTRAVI
| Drug Class | Prostacyclin Receptor Agonist |
| Mechanism of Action | Prostacyclin Receptor Agonists |
Synonyms for UPTRAVI
| 144383-EP2289518A1 |
| 144383-EP2292231A1 |
| 2-?[4-?[(5,?6-?DIPHENYLPYRAZINYL)(1-?METHYLETHYL)AMINO]BUTOXY]-?N-?(METHYLSULFONYL)-?ACETAMIDE |
| 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide |
| 2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide |
| 2-(4-((5,6-Diphenylpyrazinyl)(1-methylethyl)amino)butoxy)-N-(methylsulfonyl)-acetamide |
| 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-N-(methylsulfonyl)acetamide |
| 2-[4-[[5,6-di(phenyl)pyrazin-2-yl]-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide |
| 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide |
| 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-methanesulfonylacetamide |
| 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
| 3938AH |
| 475086-01-2 |
| 5EXC0E384L |
| ACT 293987 |
| ACT-293987 |
| ACT293987 |
| AK298890 |
| AKOS024457572 |
| B7378 |
| CHEBI:90844 |
| CHEMBL238804 |
| CS-3774 |
| CTK8F0123 |
| D09994 |
| D0N2SR |
| DB11362 |
| GTPL7552 |
| HE092855 |
| HY-14870 |
| IN2104 |
| KB-79567 |
| KS-00000L89 |
| MFCD10567093 |
| MolPort-009-019-323 |
| NS 304 |
| NS-304 |
| NS-304(Selexipag) |
| QXWZQTURMXZVHJ-UHFFFAOYSA-N |
| RT-014761 |
| SCHEMBL674122 |
| Selexipag |
| Selexipag (JAN/USAN/INN) |
| Selexipag [USAN:INN] |
| UNII-5EXC0E384L |
| Uptravi (TN) |
| ZINC3990451 |
US Patents and Regulatory Information for UPTRAVI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-007 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-006 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-008 | Dec 21, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-005 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-006 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-005 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-001 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for UPTRAVI
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Taiwan | I531565 | ➤ Sign Up |
| Croatia | P20171917 | ➤ Sign Up |
| Russian Federation | 2012102678 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 02088084 | ➤ Sign Up |
| China | 104326991 | ➤ Sign Up |
| Colombia | 6430432 | ➤ Sign Up |
| Singapore | 10201403313W | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for UPTRAVI
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2016000077 | Germany | ➤ Sign Up | PRODUCT NAME: SELEXIPAG ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083/001-010 20160512 |
| 2016 00048 | Denmark | ➤ Sign Up | PRODUCT NAME: SELEXIPAG ELLER ET SALT DERAF; REG. NO/DATE: EU/1/15/1083 20160519 |
| C0042 | France | ➤ Sign Up | PRODUCT NAME: SELEXIPAG OU L'UN DE SES SELS; REGISTRATION NO/DATE: EU/1/15/1083 20160519 |
| 0836 | Netherlands | ➤ Sign Up | PRODUCT NAME: SELEXIPAG OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1083 20160519 |
| 16/047 | Ireland | ➤ Sign Up | PRODUCT NAME: SELEXIPAG OR SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1083 20160512 |
| 266 | Luxembourg | ➤ Sign Up | PRODUCT NAME: SELEXIPAG OU UN SEL DE CELUI-CI; FIRST REGISTRATION DATE: 20160519 |
| 90044-1 | Sweden | ➤ Sign Up | PRODUCT NAME: SELEXIPAG OR SALT THEROF; REG. NO/DATE: EU/1/15/1083 20160519 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
